Bosutinib: A novel second-generation tyrosine kinase inhibitor

Recent Results in Cancer Research

Volumn 201, Issue , 2014, Pages 81-97

  Isfort, Susanne ^a   Amsberg, Gunhild Kellerv ^b   Schafhausen, Philippe ^b   Koschmieder, Steffen ^a   Brümmendorf, Tim H ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; AMINOTRANSFERASE; BCR ABL PROTEIN; BOSUTINIB; CASPASE 3; CRK ASSOCIATED SUBSTRATE PROTEIN; DIGOXIN; FOCAL ADHESION KINASE; FOCAL ADHESION KINASE 2; HYPERICUM PERFORATUM EXTRACT; IMATINIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; RIFAMPICIN; TACROLIMUS; UVOMORULIN; ANILINE DERIVATIVE; ANTINEOPLASTIC AGENT; NITRILE; PROTEIN KINASE INHIBITOR; QUINOLINE DERIVATIVE;

ABDOMINAL PAIN; ACUTE LYMPHOBLASTIC LEUKEMIA; ADVANCED CANCER; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; DIARRHEA; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; INTRACELLULAR SIGNALING; KIDNEY POLYCYSTIC DISEASE; NAUSEA; NEUTROPENIA; NON SMALL CELL LUNG CANCER; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SIDE EFFECT; SOLID TUMOR; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING; ANIMAL; METHODOLOGY; NEOPLASM; REVIEW; SALVAGE THERAPY;

ANILINE COMPOUNDS; ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NEOPLASMS; NITRILES; PROTEIN KINASE INHIBITORS; QUINOLINES; SALVAGE THERAPY;

EID: 84906928717     PISSN: 00800015     EISSN: 21976767     Source Type: Book Series    
DOI: 10.1007/978-3-642-54490-3_4     Document Type: Article

References (44)

1. Baccarani M, Cortes J et al (2013) European Leukemia Net recommendations for the management of chronic myeloid leukemia: 2013 Blood 2013 prepublished online 26 June 2013. doi:10.1182/blood-2013-05-501569
2. Bartolovic K, Balabanov S et al (2004) Inhibitory effect of imatinib on normal progenitor cells in vitro. Blood 103(2):523-529
3. Boschelli DH, Ye F et al (2001) Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Srckinaseactivity. J Med Chem 44(23):3965-3977
4. Boschelli F (2008) Activity of bosutinib, dasatinib, and nilotinibagainst 18 imatinib-resistantBcr/ Ablmutants. doi:10.1200/JCO.2008.19.8853
5. Bruemmendorf TH, Kantarjian HM et al (2012) Assessment of early molecular response as a predictor of long-term clinical outcomes in the phase 3 BELA study. Blood (ASH Annual Meeting Abstracts), Nov 2012, 120:69
6. Bruemmendorf TH, Gambacorti-Passerini C et al (2013) Efficacy and Safety of bosutinib for Philadelphia chromosome-positive leukaemia in older versus younger patients. J Clin Oncol ASCO Annual Meeting abstract, 2013 (suppl; abstr 6511)
7. Campone M, Bondarenko I et al (2012) Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy. Ann Oncol 23(3):610-617
8. Chung SW, Daniel R et al (1996) The ABL genes in normal and abnormal cell development. CritRevOncog 7(1-2):33-48
9. Coluccia AM, Benati D et al (2006) SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp 60(c-Src)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling. Cancer Res 66(4):2279-2286
10. Cortes JE, Kantarjian HM et al (2011) Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood 118(17):4567-4576
11. Cortes JE, Kim D-W et al (2012) Bosutinib versus Imatinib in newly diagnosed chronic-phase chronic myeloid leukemia; results from the BELA trial. J Clin Oncol 30(28):3486-3492
12. Daud AI, Krishnamurthi SS et al (2012) Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors. Clin Cancer Res 18(4)
13. Donato NJ, Wu JY et al (2003) BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101(2):690-698
14. Gleixner KV, Mayerhofer M et al (2011) KIT-D816V-independant oncogenic signalling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib. Blood 118(7):1885-1898
15. Golas JM, Arndt K et al (2003) SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 63(2):375-381
16. Golas JM, Lucas J et al (2005) SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models. Cancer Res 65(12):5358-5364
17. Greuber EK, Smith-Pearson P, Wang J, Pendergast AM et al. (2013) Role of ABL family kinases in cancer: from leukaemia to solid tumours. Nat Rev Cancer 13(8):559-571. doi:10.1038/nrc3563
18. Hanfstein B, Mueller C et al (2012) Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 26(9):2096-2102
19. Hegedus C, Özvegy-Laczka C et al (2009) Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol 158(4):1153-1164
20. Hu Y, Swerdlow S et al (2006) Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proc Natl Acad Sci USA 103(45):16870-16875
21. Jallal H, Valentino ML et al (2007) A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo. Cancer Res 67(4):1580-1588
22. Johnson FM, Gallick GE (2007) SRC family nonreceptor tyrosine kinases as molecular targets for cancer therapy. Anticancer Agents Med Chem 7(6):651-659
23. Khoury JH, Cortes JE et al (2012) Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood 119(15):3403-3412
24. Konig H, Holyoake TL, Bhatia R (2008) Effective and selective inhibition of chronic myeloid leukemia primitive hematopoetic progenitors by the dual Src/Abl kinase inhibitor SKI-606. Blood 111(4):2329-2338
25. Laneuville P (1995) Abl tyrosine protein kinase. Semin Immunol 7(4):255-266
26. Levinson NM, Boxer SG et al (2012) Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain. PLoS One 7(4):e29828
27. Li S (2008) Src-family kinases in the development and therapy of Philadelphia chromosomepositive chronic myeloid leukemia and acute lymphoblastic leukemia. Leuk Lymphoma 49(1):19-26
28. Lutz MP, Esser IB et al (1998) Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. Biochem Biophys Res Commun 243(2):503-508
29. Mazurenko NN, Kogan EA et al (1992) Expression of pp 60c-src in human small cell and nonsmall cell lung carcinomas. Eur J Cancer 28(2-3):372-377
30. Mueller MC, Cross NCP et al (2009) Harmonization of molecular monitoring of CML therapy in Europe. Leukemia 23:1957-1963
31. Ottenhoff-Kalff AE, Rijksen G et al (1992) Characterization of protein tyrosine kinases from human breast cancer: involvement of the c-src oncogene product. Cancer Res 52(17):4773-4778
32. Pendergast AM (1996) Nuclear tyrosine kinases: from Abl to WEE1. Curr Opin Cell Biol 8(2):174-181
33. Ptasznik A, Nakata Y et al (2004) Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells. Nat Med 10(11):1187-1189
34. Puttini M, Coluccia AM et al (2006) In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res 66(23):11314-11322
35. Redaelli S, Boschelli F et al (2010) Synergistic activity of the Src/Abl inhibitor bosutinib in combination with imatinib. Leukemia 24(6):1223-1227
36. Redaelli S, Mologni L et al (2012) Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors. Am J Hematol 87(11):E125-E128. doi:10.1002/ajh.23338. Epub 2012 Oct 9
37. Remsing LLR, Rix U et al (2009) Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia 23(3):477-485
38. Sattler M, Griffin JD (2003) Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin Hematol 40(2Suppl 2):4-10
39. Summy JM, Gallick GE (2003) Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 22(4):337-358
40. Sweeney WE, von Vigier RO (2008) Src inhibition ameliorates polycystic kidney disease. J Am Soc Nephrol 19:1331-1341
41. Thomas SM, Brugge JS (1997) Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 13:513-609
42. Verbeek BS, Vroom TM et al (1996) c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemicalanalysis. J Pathol 180(4):383-388
43. Vultur A, Buettner R et al (2008) SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells. Mol Cancer Ther 7(5):1185-1194
44. Zhang J, Kalyankrishna S et al (2007) SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines. Am J Pathol 170(1):366-376